Vihervuori et al. investigated 179 TNBC patients with complete clinical data, noting that high expression of securin was significantly associated with a low fraction of tumor-infiltrating lymphocytes and CD8+ T cells, suggesting that the level of securin expression might be useful to evaluate the tumor inflammatory response in TNBC 78. The gene discussed is CD8A; the disease is neoplasm.